Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
Having an integrated technology solution is not enough. Robust tools will be needed to assist clinicians in identifying specific and actionable steps to take based on the exact background of the patient, with his or her own genetic variation and outcomes predicted by data analysis.
Fresenius Medical Care is utilizing specific components of personalized nephrology. As an organization, we have 12 predictive models that provide personalized results to identify patients at a higher risk of hospital admissions, higher likelihood of missing a treatment, higher risk of mortality, or higher risk of progressing to ESRD. We also have multiple personalized algorithms that compute ESA doses per treatment or combine numerous variables into a functional status index.
Many of these models have proven to be successful in pilot and clinical settings. For example, the Dialysis Hospitalization Reduction (DHR) pilot was associated with a 10 percentage point reduction in hospital days over a 12-month period in participating clinics compared to non-DHR clinics in the organization.
Chronic disease management provides a good opportunity for implementing personalized holistic patient care. Typically, chronically ill patients will have multiple providers, and no one care provider has the panoramic view of the entire problem. We only "touch" some of the aspects of the disease, like the "blind men touching various parts of the elephant trying to identify what it really is."14
Personalized nephrology care and treatment provides an interesting example of transitioning from highly individualized treatment in 1962 to improvement in outcomes in recent years from standardization of care. In the near future, Fresenius Medical Care will have the opportunity to deliver personalized, precise care delivered to the right patient at the right time in the context of an organized, standardize system. This opportunity for precision medicine delivery in nephrology is made possible by general HIT advancements that promote continuous monitoring and patient engagement; sophisticated real-time data management that customizes care delivery; and advanced analytics on large data sets that support personalized treatment decisions.
LEN USVYAT, PhD
Vice President of Integrated Care Analytics, Fresenius Medical Care North America
Dr. Len Usvyat chairs Fresenius Medical Care North America's Predictive Analytics Steering Committee and works closely with the MONitoring Dialysis Outcomes (MONDO) initiative, an international consortium of dialysis providers. His team provides analytical support for the company's pharmacy, vascular care centers, urgent care facilities, hospitalist group, health plan and Medical Office research. He graduated with his PhD from the University of Maastricht in the Netherlands.